Notice is hereby given that the One Hundred and Thirty Sixth Annual General Meeting of Members will be held at the offices of The National Horseracing Authority of Southern Africa, Turf Club Street, Turffontein, on Wednesday, 17 January 2018, at 14:00 to transact the following business: 

  1. To consider and confirm the Minutes of the Annual General Meeting of Members held on Wednesday, 18 January 2017. 
  2. To consider the Report of the Chairman of the National Board of Directors for the year ended 31 July 2017. 
  3. To receive and consider the audited Financial Statements of The National Horseracing Authority of Southern Africa and the Funds held in Trust for the period ended 31 July 2017. 
  4. To appoint the Authority’s Auditors. 
  5. To transact any business which may be transacted at an Annual General Meeting.  


                                                                               Proxy Forms are available Click Here


Lyndon Barends                                                                                                                                                            15 December 2017

Chief Executive   


 The following licenses were granted at a Licensing Meeting held on 6 March 2018:  


FPP Habib (Central Province) 

D Steyn (Central Province) 



JS Roux to Trainer J van Eck (Central Province) 

Z Oosthuizen to Trainer LJ Human (Central Province) 

TI Dawson to Trainer CT Dawson (Central Province) 



J Looyen to Trainer GJ Maroun (Central Province) 

VK Ragoonath to Trainer JH Strydom (Eastern Cape) 

HJ vd Westhuizen to Trainer H vd Westhuizen (Central Province) 

IG Alli to Trainer N Kotzen (Kwa-zulu Natal) 

I Burger to Trainer LJ Human  (Central Province) 

D Kotzen to Trainer CL Bass-Robinson (Western Cape) 

K Kotzen to Trainer GS Kotzen (Western Cape) 

G Goldsmith to Trainer SJ Lerena (Central Province) 

RA Venniker to Trainer CG Eudey (Kwa-Zulu Natal) 

DR Steyn to Trainer D Steyn (Central Province) 

ML Thomas to Trainer GS Kotzen (Western Cape) 



F Zackey to Jockey CJ Habib (Central Province) 

KG Nicol to Jockey AD Andrews (Western Cape)



V Doorgapershad  - Clerk of Scales (Eastern Cape) 

SP Pati  - Specimen Collector (Eastern Cape) 

M de Vrye - Handler (Eastern Cape) 

N Thinyane  - Handler (Eastern Cape) 

J van der Hoff- Horse Identifier (Central Province) 

LA Diedericks - Specimen Collector (Western Cape)







Prednisolone hemisuccinate is a prohibited substance

Prednisolone is a corticosteroid and is a prohibited substance with a similar effect to hydrocortisone. Both prednisolone and hydrocortisone are commercially available as hemisuccinate (succinic acid) derivatives. The ester derivative, hydrocortisone hemisuccinate, is found in the preparation Solu Cortef while the similar ester, prednisolone hemisuccinate, is found in the well-known preparation Solu delta Cortef.

The term ester describes the link of the molecule succinate (succinic acid) to the corticosteroid (prednisolone) which is so-called ester linkage. This linked prednisolone hemisuccinate molecule has enhanced water solubility compared to prednisolone itself. Contained in injectable formulations, this ester derivative permits the intravenous administration of higher doses of prednisolone than otherwise possible.

When injected the prednisolone hemisuccinate is broken down in the body (the ester is hydrolysed) resulting in the release of prednisolone, the active corticosteroid molecule.

Prednisolone hemisuccinate is therefore not only an ester derivative but also a pro-drug of prednisolone. A pro-drug is defined as a precursor of a drug molecule that results in the formation of the drug (in this case prednisolone).

The hydrolysis of prednisolone hemisuccinate is not immediate. This ester derivative can be detected in both blood and urine for a period of at least 24 hours following the intravenous administration of a normal dose of a prednisolone hemisuccinate preparation (such as Solu delta Cortef).

As described in Rule 73.4, pro-drugs of prohibited substances and metabolites of prohibited substances are also prohibited substances. The administration of injected prednisolone hemisuccinate can therefore result in positive declarations on prednisolone hemisuccinate and/or prednisolone and/or known metabolites of prednisolone.